Ironwood Pharmaceuticals, Inc. filings document a Nasdaq-listed biotechnology company focused on gastrointestinal and rare disease therapies. Its Form 8-K reports include operating and financial results, business updates for LINZESS and apraglutide, regulatory and pricing matters involving LINZESS, and financing-related disclosures tied to credit agreements and liquidity conditions.
Proxy filings cover board elections, executive compensation votes, equity incentive plan matters, auditor ratification, and annual meeting procedures. Other filings address governance changes, Nasdaq listing-compliance matters for its Class A common stock, and the registered security structure of IRWD shares on the Nasdaq Global Select Market.
Ironwood Pharmaceuticals reported a profitable quarter but a loss for the first half of 2025. For the three months ended June 30, 2025 the company recorded $23.6 million of net income (basic EPS $0.15), driven by collaborative arrangements revenue of $85.2 million and reduced operating costs. For the six months ended June 30, 2025, revenue from collaborative arrangements was $126.4 million versus $169.3 million a year earlier, and the company recorded a $13.8 million net loss for the period.
The balance sheet shows $92.9 million of cash and cash equivalents and accounts receivable of $86.2 million, largely due from AbbVie. Current liabilities increased sharply to $232.5 million primarily because the $200.0 million 2026 Convertible Notes are presented, in part, as a current obligation (net carrying amount $199.3 million) and these notes mature on June 15, 2026. Management states available liquidity and borrowing capacity are sufficient to meet operations for at least the next 12 months.
This Form 144 notifies a proposed sale of 8,281 shares of Ironwood Pharmaceuticals, Inc. Class A common stock with an aggregate market value of $7,287.28. The sale is listed to occur through E Trade Securities LLC on the Nasdaq exchange on 08/11/2025. The securities were originally acquired as a Restricted Stock Unit award under the issuer's 2019 Equity Incentive Plan on 08/02/2021, with 19,973 units shown as acquired on that date.
The filing reports 161,819,848 shares outstanding, and indicates no securities sold in the past three months by the person for whose account the sale is filed. The notice includes the filer's representation that they do not know of any undisclosed material adverse information regarding the issuer.
Ironwood Pharmaceuticals filed a Form 144 reporting a proposed sale of 1,351 shares of Class A common stock on Nasdaq, with an aggregate market value of $1,188.88. The sale is listed with an approximate sale date of 08/11/2025. The filer acquired 4,000 shares as a Restricted Stock Unit award on 08/16/2023, and no securities of the issuer were reported sold by the filer in the past three months.
The filing includes the filer’s representation that they are not aware of any undisclosed material adverse information about the issuer. The shares to be sold amount to approximately 0.000835% of the 161,819,848 shares outstanding, indicating a very small proposed disposition relative to the company’s market capitalization.
Ironwood Pharmaceuticals Form 144 reports that Tammi Gaskins proposes to sell 1,406 shares of Class A common stock on 08/11/2025 through E Trade (Nasdaq), with an aggregate market value of $1,237.28. The filing states these shares were acquired as 4,000 restricted stock units granted on 08/16/2023.
The notice also discloses a prior sale of 2,563 shares on 05/16/2025 for gross proceeds of $1,486.54. The filer affirms they do not possess undisclosed material adverse information.